FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population

[1]  F. Jessen,et al.  Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer , 2017, JAMA oncology.

[2]  Lara E Sucheston-Campbell,et al.  Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene , 2017, Oncotarget.

[3]  P. Broderick,et al.  Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic Review. , 2017, Gastroenterology.

[4]  Tom Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[5]  Madalena Tarsounas,et al.  Interplay between Fanconi anemia and homologous recombination pathways in genome integrity , 2016, The EMBO journal.

[6]  R. Winqvist,et al.  Targeted Next-Generation Sequencing Identifies a Recurrent Mutation in MCPH1 Associating with Hereditary Breast Cancer Susceptibility , 2016, PLoS genetics.

[7]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[8]  Eliseos J. Mucaki,et al.  FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. , 2015, Human molecular genetics.

[9]  J. Schleutker,et al.  Finnish Fanconi anemia mutations and hereditary predisposition to breast and prostate cancer , 2015, Clinical genetics.

[10]  Brigitte Rack,et al.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Martin Kircher,et al.  Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. , 2015, Cancer discovery.

[12]  R. Winqvist,et al.  Recurrent CYP2C19 deletion allele is associated with triple-negative breast cancer , 2014, BMC Cancer.

[13]  F. Couch,et al.  Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer , 2014, Proceedings of the National Academy of Sciences.

[14]  Andres Metspalu,et al.  Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population , 2014, PLoS genetics.

[15]  P. Ang,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[16]  Howard L McLeod,et al.  Exome Resequencing Identifies Potential Tumor‐Suppressor Genes that Predispose to Colorectal Cancer , 2013, Human mutation.

[17]  S. Fox,et al.  Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes , 2013, PloS one.

[18]  J. Benítez,et al.  Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2 Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles , 2013, PloS one.

[19]  A. D’Andrea,et al.  Molecular pathogenesis and clinical management of Fanconi anemia. , 2012, The Journal of clinical investigation.

[20]  A. Kallioniemi,et al.  Rare Copy Number Variants Observed in Hereditary Breast Cancer Cases Disrupt Genes in Estrogen Signaling and TP53 Tumor Suppression Network , 2012, PLoS genetics.

[21]  A. D’Andrea,et al.  Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway. , 2011, DNA repair.

[22]  Shiaw-Yih Lin,et al.  DNA damage and breast cancer. , 2011, World journal of clinical oncology.

[23]  J. Schleutker,et al.  RAD51C is a susceptibility gene for ovarian cancer. , 2011, Human molecular genetics.

[24]  F. Schmitt,et al.  Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool? , 2011, BMC Cancer.

[25]  A. Mannermaa,et al.  ST14 Gene Variant and Decreased Matriptase Protein Expression Predict Poor Breast Cancer Survival , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[26]  J. Brunet.  Hereditary breast cancer and genetic counseling in young women , 2010, Breast Cancer Research and Treatment.

[27]  Dieter Niederacher,et al.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[28]  M. Whitby.  The FANCM family of DNA helicases/translocases. , 2010, DNA repair.

[29]  H. Joenje,et al.  Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M. , 2009, Human molecular genetics.

[30]  M. Gandhi,et al.  Selective accumulation of virus-specific CD8+ T cells within the peripheral blood stem cell compartment. , 2009, Blood.

[31]  David A. Williams,et al.  Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M. , 2009, Blood.

[32]  Päivi Heikkilä,et al.  NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer , 2008, Nature Genetics.

[33]  Tom Walsh,et al.  Ten genes for inherited breast cancer. , 2007, Cancer cell.

[34]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[35]  Päivi Heikkilä,et al.  Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients , 2005, International journal of cancer.

[36]  D. Easton,et al.  An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  Päivi Heikkilä,et al.  Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families , 2004, Breast Cancer Research.

[38]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[39]  H. Nevanlinna,et al.  BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients , 2001, European Journal of Human Genetics.

[40]  H. Nevanlinna,et al.  A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.

[41]  K Holli,et al.  Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.

[42]  H. Nevanlinna,et al.  Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? , 2000, European journal of cancer.

[43]  O. Kallioniemi,et al.  Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. , 1997, Human molecular genetics.

[44]  P. Frankland.  On the Evolution of Heat During Muscular Action1 , 1878, Nature.